The influx of reports also highlights shortcomings of how the U.S. tracks safety risks and outcomes for FDA-approved drugs. The FDA itself cautions that the database, known as FAERS, can reflect underreporting and overreporting of events, as well as duplicates, and incomplete information about what happened. In 2017, the agency put an interactive version of the data online, in hopes of attracting more detailed reports from consumers and doctors.